Comparing of Eloxx Pharmaceuticals Inc. (ELOX) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP)

Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals Inc. 5 0.00 21.81M -1.47 0.00
ANI Pharmaceuticals Inc. 67 5.30 9.24M 1.15 73.62

Table 1 highlights Eloxx Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Eloxx Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals Inc. 481,456,953.64% -107.1% -88.5%
ANI Pharmaceuticals Inc. 13,838,550.25% 7% 3.1%

Risk & Volatility

Eloxx Pharmaceuticals Inc. is 71.00% more volatile than Standard and Poor’s 500 because the company has a beta of 1.71. ANI Pharmaceuticals Inc.’s 116.00% more volatile than Standard and Poor’s 500 which is a result of the 2.16 beta.

Liquidity

The Current Ratio of Eloxx Pharmaceuticals Inc. is 6.6 while its Quick Ratio stands at 6.6. The Current Ratio of rival ANI Pharmaceuticals Inc. is 0.9 and its Quick Ratio is has 0.7. Eloxx Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Recommendations

In next table is given Eloxx Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eloxx Pharmaceuticals Inc. 0 0 0 0.00
ANI Pharmaceuticals Inc. 0 0 2 3.00

On the other hand, ANI Pharmaceuticals Inc.’s potential upside is 26.74% and its consensus target price is $75.5.

Insider & Institutional Ownership

Roughly 50.1% of Eloxx Pharmaceuticals Inc. shares are owned by institutional investors while 86.2% of ANI Pharmaceuticals Inc. are owned by institutional investors. Eloxx Pharmaceuticals Inc.’s share owned by insiders are 0.4%. On the other hand, insiders owned about 3.3% of ANI Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eloxx Pharmaceuticals Inc. -0.12% -17.66% -28.55% -29.23% -46.1% -32.06%
ANI Pharmaceuticals Inc. 1.72% 2.27% 20.43% 55.98% 25.49% 87.89%

For the past year Eloxx Pharmaceuticals Inc. has -32.06% weaker performance while ANI Pharmaceuticals Inc. has 87.89% stronger performance.

Summary

ANI Pharmaceuticals Inc. beats on 8 of the 12 factors Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.